Associations between lifetime agoraphobia status at baseline and inflammatory measures (composite score) at follow-up, serially adjusted for covariates.

Values for inflammatory measures are given as unadjusted log10-transformed means ± standard deviation, values for interleukin-1β are given as prevalence.
HDL, high-density lipoprotein; CRP, C-reactive protein; TNF, tumor necrosis factor; OR, odds ratio; 95CI, 95% confidence interval.
a Duration between somatic evaluation at baseline and somatic evaluation at follow-up.
b A value of “3” represents an SES of III (middle class) on the Hollingshead Scale.
c Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg.
d Physically active at least or more than 20 minutes twice a week.
e Generalized anxiety disorder, panic disorder, posttraumatic stress disorder, and/or social phobia.
f Marijuana, cocaine, solvent, hallucinogen, stimulant, sedative or/and narcotic dependence.
g Multiple regression with log10 transformed cytokine or CRP or adiponectin.
h Logistic regression with interleukin-1β concentration dichotomized at the median.
i Composite score of inflammatory markers includes CRP, interleukin-6 and TNF-α. Only participants who had data available for all three of these markers were included in these analyses.
Associations between lifetime agoraphobia status at baseline and inflammatory measures (composite score) at follow-up, serially adjusted for covariates.